Omeros | OMER - Net Income


Omeros reported $-32.23M in Net Income for its fiscal quarter ending in September of 2024.





Net Income Change Date
Adma Biologics USD 36.43M 2.21M Sep/2025
Alnylam Pharmaceuticals USD 251.08M 317.36M Sep/2025
BioMarin Pharmaceutical USD -30.74M 271.28M Sep/2025
Cytokinetics USD -306.18M 171.81M Sep/2025
Dynavax Technologies USD 18.72M 114.82M Jun/2025
Gilead Sciences USD 2.18B 869M Dec/2025
Heron Therapeutics USD -4.85M 4.39M Sep/2024
Immunic USD -24.37M 2.99M Sep/2024
Insmed USD -370.02M 48.34M Sep/2025
Knight Therapeutics CAD 85K 2.03M Sep/2024
MacroGenics USD 16.82M 53.07M Sep/2025
Omeros USD -32.23M 23.81M Sep/2024
Pacira USD 5.43M 10.28M Sep/2025
Pfizer USD -1.65B 5.19B Dec/2025
Rockwell Medical USD 343K 2.07M Jun/2024
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Sarepta Therapeutics USD -179.95M 376.84M Sep/2025
United Therapeutics USD 338.7M 29.2M Sep/2025
Vertex Pharmaceuticals USD 1.08B 50M Sep/2025
Xoma USD -17.24M 33.23M Sep/2024